Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States

作者：Matthew Stargardter, Ali McBride, Jonathan Tosh, Rameet Sachdev, Mo Yang, Apoorva Ambavane, Madhav Mittal, H. Vioix, Frank Xiaoqing Liu · 发表于：Journal of Medical Economics · 年份：2021 · DOI：10.1080/13696998.2021.1942017 · 被引用次数：8 · 研究领域：Health Systems, Economic Evaluations, Quality of Life、Lung Cancer Treatments and Mutations、Economic and Financial Impacts of Cancer

Aims To estimate the budget impact of adding tepotinib to United States (US) health plans for treating adult patients with metastatic non-small cell lung cancer (mNSCLC) harboring mesenchymal–epithelial transition exon 14 (METex14) skipping alterations.Methods The base-case analysis was conducted from the perspective of a hypothetical Medicare plan of 1 million members. Scenarios were analysed for other US health plans. Treatments included tepotinib, capmatinib, crizotinib, and standard of care (SoC). Patients eligible for tepotinib were estimated from published epidemiological data and literature, and real-world evidence. Clinical inputs were derived from the phase II VISION trial, US prescribing information, and published literature. Tepotinib uptake and projected testing rates for METex14 skipping alterations were based on market research. Unit costs (2020 US dollars (USD)) and resource utilization associated with drug acquisition and administration, treatment monitoring, disease and adverse event (AE) management, and subsequent treatment were derived primarily from public sources.Results In the base-case, 38–65 patients were eligible for tepotinib each year over the three-year time horizon. The cumulative net budgetary impact of tepotinib was –$692,541 (–2.6%); $26,531,670 in the scenario without tepotinib and $25,839,129 in the scenario with tepotinib. A negligible net budget impact was observed per member per month (PMPM) at $0.2457 and $0.2393, respectively, before and...